GlobeNewswire·Jul 20, 2026, 7:30 AM ET

BrainsWay Announces Strategic Investment in Radial Health, Inc.

BrainsWay Ltd. announced a $3 million minority equity investment in Radial Health, Inc. on July 20, 2026.
The investment is part of Radial's previously announced Series A financing & BrainsWay joins other investors including General Catalyst, Floating Point Capital, Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital, & Diede van Lamoen.
Radial specializes in clinical infrastructure, reimbursement tools, & an AI-guided decision support platform for "Brain Medicine" treatments like Deep TMS™.
The financing is expected to support Radial's exploration of various M&A opportunities & expansion of its clinical footprint.
Hadar Levy, BrainsWay's CEO, stated the investment aligns with the company's strategy to secure minority equity in high-performing mental health provider networks.
John Capecelatro, Radial's CEO & co-founder, noted the capital will strengthen the technology platform & increase access to evidence-based Brain Medicine options.
Advocates Ami Hordes & Sarit Molcho of S. Friedman, Abramson & Co. Law Offices served as lead counsel for BrainsWay on the transaction.
BrainsWay holds three FDA-cleared indications for Deep TMS™ covering major depressive disorder, obsessive-compulsive disorder, & smoking addiction.
The press release includes standard forward-looking statements regarding risks such as regulatory approvals, reimbursement delays, & competition.